Enhanced Bladder Cancer Treatment via Engineered Antigen Presenting Cells and BCG-Based Therapies

This invention envisions a next-generation bladder cancer treatment system that combines the immunotherapeutic potential of Bacillus Calmette-Guerin (BCG) with engineered antigen presenting cells, enhancing the immune response to bladder cancer cells.

The original patent disclosed the use of BCG and antigen presenting cells for bladder cancer treatment, but it had limitations in terms of efficacy and targeting specificity. This new inventive concept addresses these limitations by introducing engineered antigen presenting cells that selectively target bladder cancer cells, thereby enhancing the immune response and improving treatment outcomes.

The inventive concept comprises a system for treating bladder cancer, which includes a BCG-based therapeutic composition and an antigen presenting cell-based vaccine. The antigen presenting cells are engineered to selectively target bladder cancer cells and are administered in conjunction with the BCG-based therapeutic composition to enhance the immune response to bladder cancer cells. The system may also include a sensor for detecting the presence of antigen presenting cells in a subject's urine, allowing for real-time monitoring and treatment optimization.

The new claims introduce the concept of engineered antigen presenting cells that selectively target bladder cancer cells, which is a significant departure from the original patent. This inventive step enables a more targeted and effective immune response, making the treatment more efficient and reducing potential side effects.

Alternative embodiments of the inventive concept may include the use of different types of antigen presenting cells, such as dendritic cells or macrophages, or the incorporation of additional immunotherapeutic agents, such as checkpoint inhibitors. Variations may also include the use of different routes of administration, such as intravesical or systemic delivery.

The inventive concept has significant commercial potential in the treatment of bladder cancer, which is a major unmet medical need. The market for bladder cancer treatments is expected to grow significantly in the coming years, and this inventive concept is well-positioned to capitalize on this trend.